Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer
In this cohort study of patients with mCRPC, initiation of enzalutamide was associated with small but statistically significant improvements in OS, PCS, TTS, and TTR compared with initiation of abiraterone acetate. The improvements were more prominent in short-term outcomes, including TTS and TTR, and in patient subgroups without prior docetaxel or with PSA doubling time longer than 3 months.
Authors
- Deborah Lang (ORCID: https://orcid.org/0000-0003-1057-0923)
- June K. Corrigan (ORCID: https://orcid.org/0000-0002-7514-0177)
- Nhan Do (ORCID: https://orcid.org/0000-0001-6868-7011)
- Jennifer La (ORCID: https://orcid.org/0000-0003-2266-0221)
- Nathanael R. Fillmore (ORCID: https://orcid.org/0000-0002-8058-3423)
- Mary T. Brophy (ORCID: https://orcid.org/0000-0003-2314-4368)
- Channing Judith Paller (ORCID: https://orcid.org/0000-0003-3658-1858)
- Lin Wang (ORCID: https://orcid.org/0000-0002-0503-9727)
- Michelle Lee (ORCID: https://orcid.org/0000-0002-7847-4471)
Institutions
- Boston University (US)
- Harvard University (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- VA Boston Healthcare System (US)
- Massachusetts General Hospital (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2024-08-16
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.28444
- Citations
- 7
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.93